FYFanghang Ye

Fanghang Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fanghang Ye has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Yu

    Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China; Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

    3 shared publications
  • Fei Yu

    Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China

    3 shared publications
  • Na Li

    Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China; Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

    3 shared publications
  • Xiaoyu Hu

    Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

    3 shared publications
  • Yucheng Huang

    Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China; Department of Rheumatology and Immunology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

    3 shared publications
  • Jiali Deng

    Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China; Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

    2 shared publications

Latest Publications

  • Ginsenosides in Liver Fibrosis: Pharmacological Actions and Therapeutic Potential

    by Na Li, Fanghang Ye, Fei Yu, Liyuan Hao, Shenghao Li, Qing Peng, Jiali Deng, Junli Zhang, Xiaoyu Hu

    Liver fibrosis (LF) represents a critical pathological stage in the progression of various chronic liver diseases, and is characterized by the sustained activation of hepatic stellate cells (HSCs) and excessive deposition of extracellular matrix (ECM). These processes ultimately lead to cirrhosis and even hepatocellular carcinoma. Current therapeutic strategies for LF primarily rely on etiological interventions and supportive management. However, due to the complex pathogenesis of LF, involving multiple interconnected signaling pathways, effective and specific antifibrotic therapies remain lacking. Therefore, the development of multi-target and system-level therapeutic strategies for the treatment of LF is of considerable importance. Ginsenosides, the major bioactive components of Panax ginseng, exhibit multi-component and multi-target pharmacological properties and have shown broad potential in the prevention and treatment of liver fibrosis. Accumulating evidence indicates that several ginsenosides, including Rg1, Rb1, Rg3, Rh1, Rd, and the metabolite Compound K, exert significant antifibrotic effects across various experimental models. This review systematically summarizes the pharmacological mechanisms of ginsenosides in liver fibrosis and integrates their effects from a mechanistic perspective. Overall, ginsenosides directly target key fibrogenic processes by inhibiting HSCs activation and proliferation, promoting apoptosis, reducing ECM synthesis, and facilitating ECM degradation. In addition, they indirectly modulate fibrosis progression by regulating upstream amplifying factors such as inflammation, oxidative stress, and the immune microenvironment. Furthermore, ginsenosides also influence cell fate-related processes, including autophagy and ferroptosis, in a cell-type-dependent manner. In hepatocytes, maintaining appropriate autophagic activity and suppressing lipid peroxidation generally confers protective effects. In HSCs, by contrast, the inhibition of protective autophagy or induction of ferroptosis appears to be more relevant to antifibrotic efficacy. Although substantial experimental evidence supports the antifibrotic potential of ginsenosides, their clinical translation remains limited by low bioavailability, unclear active forms in vivo, and the lack of high-quality clinical studies. Future investigations should focus on identifying key molecular targets and underlying mechanisms through multi-omics approaches and structure–activity relationship analyses. Well-designed clinical trials should likewise be conducted to evaluate the safety and therapeutic efficacy of ginsenosides and, thereby, facilitate their clinical application in liver fibrosis.

  • Open Access

    Post-Translational Modifications of NTCP: A Regulatory Nexus for Bile Acid Transport and HBV Entry

    by Fei Yu, Yue Zhu, Na Li, Qing Peng, Fanghang Ye, Qianlan Luo, Jiajun Xia, Xiaoyu Hu

    The sodium-taurocholate cotransporting polypeptide (NTCP) plays a critical dual role in liver function: maintaining bile acid (BA) enterohepatic circulation and acting as a receptor for the entry of hepatitis B and D viruses into hepatocytes. This review outlines the impact of various post-translational modifications (PTMs) of NTCP—including phosphorylation, oligomerization, ubiquitination, and glycosylation—on its dynamic regulatory network. These modifications coordinate the modulation of NTCP’s membrane localization, stability, conformational state, and protein interactions, precisely controlling its functions in BA uptake and viral invasion. Targeting this PTM network presents a promising strategy for next-generation therapies that selectively inhibit viral infection while preserving BA transport, overcoming the limitations of conventional inhibitors that indiscriminately disrupt virus–NTCP interactions. By synthesizing recent insights into NTCP PTM research, this article highlights its role as a central regulator of its bifunctional properties and reveals potential avenues for precision therapies in viral hepatitis, cholestasis, and related liver diseases. However, most existing evidence is derived from in vitro or cell-based models, whereas in vivo studies and clinical validation remain limited; thus, the translational feasibility of strategies targeting post-translational modifications of NTCP still requires further investigation.

  • Open Access

    Morphological alterations and gene expression levels in the cerebral cortex causally influence susceptibility to type 2 diabetes: A Mendelian randomization study

    by Fanghang Ye, Yucheng Huang, Na Li, Liyuan Hao, Jiali Deng, Shenghao Li, Jiayun Yue, Fei Yu, Xiaoyu Hu


  • Open Access

    The Culprit Behind HBV-Infected Hepatocytes: NTCP

    by Shenghao Li, Liyuan Hao, Jiali Deng, Junli Zhang, Fei Yu, Fanghang Ye, Na Li, Xiaoyu Hu

    Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for over 250 million cases of chronic liver infections, leading to conditions such as liver inflammation, cirrhosis and hepatocellular carcinoma (HCC). Sodium taurocholate co-transporting polypeptide (NTCP) is a transmembrane protein highly expressed in human hepatocytes and functions as a bile acid (BA) transporter. NTCP has been identified as the receptor that HBV and its satellite virus, hepatitis delta virus (HDV), use to enter hepatocytes. HBV entry into hepatocytes is tightly regulated by various signaling pathways, and NTCP plays an important role as the initial stage of HBV infection. NTCP acts as an initiation signal, causing metabolic changes in hepatocytes and facilitating the entry of HBV into hepatocytes. Thus, a comprehensive understanding of NTCP’s role is crucial. In this review, we will examine the regulatory mechanisms governing HBV pre-S1 binding to liver membrane NTCP, the role of NTCP in HBV internalization, and the transcriptional and translational regulation of NTCP expression. Additionally, we will discuss clinical drugs targeting NTCP, including combination therapies involving NTCP inhibitors, and consider the safety of NTCP as a therapeutic target.


  • Open Access

    The genetically predicted causal associations between circulating 3-hydroxybutyrate levels and malignant neoplasms: A pan-cancer Mendelian randomization study

    by Fanghang Ye, Yucheng Huang, Liang Zeng, Na Li, Liyuan Hao, Jiayun Yue, Shenghao Li, Jiali Deng, Fei Yu, Xiaoyu Hu